Details

Autor(en) / Beteiligte

• Gargiulo, Giuseppe
• Cirillo, Plinio
• Sperandeo, Luca
• Forzano, Imma
• Castiello, Domenico Simone
• Florimonte, Domenico
• Simonetti, Fiorenzo
• Paolillo, Roberta
• Manzi, Lina
• Spinelli, Alessandra
• Spaccarotella, Carmen Anna Maria
• Piccolo, Raffaele
• Di Serafino, Luigi
• Franzone, Anna
• Capranzano, Piera
• Valgimigli, Marco
• Esposito, Giovanni

Titel

Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: Pharmacodynamic data from the POMPEII study

Ist Teil von

• International journal of cardiology. Heart & vasculature, 2024-02, Vol.50, p.101344-101344, Article 101344

Ort / Verlag

Ireland: Elsevier B.V

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• There are limited data to assess pharmacodynamic (PD) profiles of patients with STEMI undergoing primary percutaneous coronary intervention (PCI) and receiving cangrelor after pretreatment with ticagrelor. The PharmacOdynaMic effects of cangrelor in PatiEnts wIth acute or chronIc coronary syndrome undergoing percutaneous coronary intervention (POMPEII) registry (NCT04790032) is a prospective study conducted at Federico II University of Naples enrolling all patients undergoing PCI receiving cangrelor at operator’s discretion. PD assessments were performed with 3 assays: (1) the gold standard light transmittance aggregometry (LTA) (20- and 5-μM adenosine diphosphate [ADP] stimuli); (2) VerifyNow P2Y12-test; (3) Multiplate electrode aggregometry (MEA), ADP-test. We analyzed 13 STEMI patients pretreated with ticagrelor within 1 h at the time they underwent primary PCI receiving cangrelor. All patients showed low maximal platelet aggregation at 30-minute during cangrelor infusion, as well as at 3 h and 4–6 h (corresponding to 1 h and 2–4 h after stopping cangrelor infusion) with no cases of high residual platelet reactivity. These results were consistent with all assays. PD data show that in contemporary real-world STEMI patients pretreated within 1 h with ticagrelor undergoing primary PCI, adding cangrelor resulted in fast and potent platelet inhibition, thus suggesting that cangrelor may bridge the gap until ticagrelor reaches its effect.